Posted by Michael Wonder on 23 Oct 2018
NZ patients with ALK positive non-small-cell lung cancer score a minor win
23 October 2018 - PTAC has recommended that alectinib hydrochloride be funded for the first-line treatment of ALK positive, locally advanced or metastatic non-small cell lung cancer with medium priority.
PTAC also recommended that the application be referred to the Cancer Treatments Subcommittee for advice regarding appropriate Special Authority criteria so its listing in the New Zealand Pharmaceutical Schedule may take a while.
PTAC reiterated its previous recommendation that crizotinib for the first and second-line treatment of ALK positive advanced NSCLC be declined due to concerns regarding trial design and poor cost-effectiveness at the proposed price.
